Diltiazem Dose Escalation from 120mg
The next appropriate dose when increasing from diltiazem 120mg is 180mg once daily for extended-release formulations, with subsequent titration to 240mg, then 360mg based on response and tolerability. 1
Standard Dose Escalation Protocol
Initial Titration Steps
- Start with 180mg once daily as the first dose increase from 120mg for extended-release (CD) formulations 1
- The American College of Cardiology recommends a dosing range of 120-360mg daily for hypertension and angina, with most patients requiring doses above 120mg for adequate blood pressure control 1
- Titrate cautiously and progressively over several weeks to reach effective control, monitoring blood pressure and heart rate at each step 1
Target Dosing by Indication
- For hypertension: The therapeutic range is typically 240-360mg daily, as doses of 90-120mg/day represent a "no-effect dose" for blood pressure lowering 2
- For angina: The typical effective dose is 240mg daily, which is lower than hypertension requirements 2
- For pulmonary arterial hypertension (if vasoreactive): High doses of 240-720mg daily are used, starting at 60mg three times daily and increasing progressively 3
Dose-Response Relationship
Evidence for Higher Dosing
- A clear linear dose-response relationship exists through the 480-540mg/day range for blood pressure lowering 2, 4
- Doses of 240-480mg significantly lower blood pressure in a dose-related fashion, with incremental benefits at each escalation 5, 4
- The 360mg dose is often the optimal maintenance dose for most patients with hypertension, though many are underdosed at 180-240mg 2
Maximum Dosing
- The maximum maintenance dose is 360mg daily for most indications per American College of Cardiology guidelines 1
- Doses up to 540mg daily have been studied and found safe for hypertension, though adverse effects increase in a dose-related manner 5, 4
Monitoring During Titration
Critical Parameters to Assess
- Blood pressure and heart rate should be monitored regularly during dose escalation 1
- Reassess patients 1 month after each dose change to evaluate efficacy and tolerability 1
- Watch for return of symptoms (elevated blood pressure, angina, or rapid heart rate) indicating inadequate dosing 1
Dose-Limiting Adverse Effects
- Hypotension is the most common adverse effect and may limit dose escalation 3, 1
- Peripheral edema is dose-related and more common in women; consider adding diuretics if this occurs 3, 1
- Bradycardia may be dose-limiting, particularly at the 360mg dose or when combined with beta-blockers 1, 6
- Constipation can be severe enough to require dose reduction, especially in elderly patients 6
Special Considerations
When to Stop at Lower Doses
- Elderly patients (71-82 years) may achieve optimal benefit at 180mg daily, with higher doses causing more adverse effects without additional efficacy for angina 6
- Patients with baseline bradycardia should be monitored closely, as diltiazem is preferred in those with relative tachycardia 3, 1
Contraindications to Further Escalation
- Do not increase dose in patients with second or third-degree AV block without a pacemaker, decompensated heart failure, severe LV dysfunction, or symptomatic hypotension 1, 7
- Avoid combination with beta-blockers during dose escalation due to risk of significant bradyarrhythmias and heart failure 1
- Use caution in patients with PR interval >0.24 seconds, as this increases risk of heart block 1
Drug Interactions Affecting Dosing
- Diltiazem is a CYP3A4 substrate and moderate inhibitor; reduce warfarin dose by 50% and digoxin dose by 30-50% when escalating diltiazem 1
- Exercise caution with apixaban, cyclosporine, simvastatin, and other CYP3A4 substrates when increasing diltiazem dose 1, 7
Practical Dosing Algorithm
- From 120mg → 180mg once daily: Monitor for 2-4 weeks 1
- If inadequate response → 240mg once daily: This is the minimum effective dose for most hypertension patients 2
- If still inadequate → 360mg once daily: This is the optimal maintenance dose for most patients 1, 2
- Consider 480-540mg only if: Patient tolerates 360mg well but remains uncontrolled, with close monitoring for adverse effects 5, 4